SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Positron emission tomography/computed tomography (PET/CT) is an advanced nuclear medicine
scan. This technology allows precise and early cancer to be visualized and measured on whole
body images. Patients with Neuro-Endocrine tumors (NETs), require specialized molecular
imaging to stage, re-stage and assess eligibility and response to therapy. 68Ga-DOTATATE is a
nuclear medicine imaging agent that is not yet approved by Health Canada but used extensively
throughout the world. The Ki-67 index, a marker of cell proliferation in NETs, is one of the
most important prognostic factors in this disease. The objective of this study is to evaluate
if the maximal standard uptake value (SUVmax) on PET/CT in NETs inversely correlates with
Ki-67 score on initial biopsy. If this hypothesized correlation between SUV and Ki-67 score
is reproduced, then DOTATATE would serve as a non-invasive method to assess cellular
proliferation and therefore prognosis of these patients.